$784 Million is the total value of Sarissa Capital Management LP's 12 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 23.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BIIB | BIOGEN INC | $203,432,000 | +6.6% | 643,000 | 0.0% | 25.95% | +63.9% | |
| IRWD | Buy | IRONWOOD PHARMACEUTICALS INC | $136,467,000 | -0.5% | 13,525,000 | +31.2% | 17.41% | +52.9% |
| ALKS | Buy | ALKERMES PLC | $103,723,000 | +33.6% | 7,193,000 | +89.0% | 13.23% | +105.4% |
| AGN | ALLERGAN PLC | $82,794,000 | -7.4% | 467,500 | 0.0% | 10.56% | +42.4% | |
| JAZZ | Buy | JAZZ PHARMACEUTICALS PLC | $76,301,000 | +15.2% | 765,000 | +72.5% | 9.73% | +77.1% |
| INVA | INNOVIVA INC | $73,405,000 | -16.9% | 6,242,000 | 0.0% | 9.36% | +27.7% | |
| ICPT | Buy | INTERCEPT PHARMACEUTICALS INC | $72,718,000 | -31.8% | 1,155,000 | +34.3% | 9.28% | +4.9% |
| MRSN | MERSANA THERAPEUTICS INC | $21,862,000 | +1.7% | 3,750,000 | 0.0% | 2.79% | +56.4% | |
| ALXN | New | ALEXION PHARMACEUTICALS INC | $12,121,000 | – | 135,000 | +100.0% | 1.55% | – |
| RGLS | REGULUS THERAPEUTICS INC | $853,000 | -48.2% | 1,851,851 | 0.0% | 0.11% | -20.4% | |
| ABBV | ABBVIE INC | $76,000 | -13.6% | 1,000 | 0.0% | 0.01% | +42.9% | |
| MRTX | MIRATI THERAPEUTICS INC | $76,000 | -40.6% | 1,000 | 0.0% | 0.01% | -9.1% | |
| Exit | MEDICINES COnote 3.500% 1/1 | $0 | – | -20,000,000 | -100.0% | -5.68% | – | |
| MDCO | Exit | MEDICINES CO | $0 | – | -4,202,000 | -100.0% | -29.62% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC. | 32 | Q3 2023 | 37.1% |
| INNOVIVA INC. | 29 | Q3 2023 | 19.5% |
| IRONWOOD PHARMACEUTICALS INC. | 24 | Q3 2023 | 24.2% |
| ABBVIE INC. | 23 | Q2 2020 | 24.4% |
| MEDICINES CO. | 20 | Q4 2019 | 33.9% |
| MERSANA THERAPEUTICS INC. | 19 | Q3 2023 | 7.9% |
| ALKERMES PLC | 16 | Q3 2023 | 43.7% |
| INTERCEPT PHARMACEUTICALS INC. | 15 | Q2 2021 | 10.7% |
| BIOCRYST PHARMACEUTICALS INC | 14 | Q3 2023 | 7.4% |
| VIVUS INC | 14 | Q1 2017 | 8.8% |
View Sarissa Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Alkermes plc. | August 24, 2023 | 8,323,400 | 5.0% |
| Innoviva, Inc. | May 15, 2023 | 6,904,000 | 10.5% |
| IRONWOOD PHARMACEUTICALS INC | March 01, 2021 | 14,890,000 | 9.3% |
| Iterum Therapeutics plcSold out | February 12, 2021 | 0 | 0.0% |
| BIOCRYST PHARMACEUTICALS INC | January 25, 2021 | 8,844,000 | 5.0% |
| Mersana Therapeutics, Inc. | January 25, 2021 | 3,770,000 | 5.5% |
| MEDICINES CO /DESold out | January 07, 2020 | 0 | 0.0% |
| Regulus Therapeutics Inc. | January 03, 2020 | 7,935,322 | 29.4% |
| NOVELION THERAPEUTICS INC. | November 09, 2018 | 909,296 | 4.6% |
| APRICUS BIOSCIENCES, INC. | September 05, 2018 | 1,152,455 | 4.8% |
View Sarissa Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-03-19 |
| 13F-HR | 2024-02-14 |
| 4 | 2023-12-19 |
| SC 13D/A | 2023-12-05 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-19 |
| SC 13D/A | 2023-09-05 |
| SC 13D/A | 2023-08-24 |
| 13F-HR | 2023-08-14 |
| DFAN14A | 2023-06-28 |
View Sarissa Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.